Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Code of Conduct [a]
CC transcript
EyePoint Pharmaceuticals, Inc. (EYPT) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/02/2023 8-K Quarterly results
07/27/2023 8-K Investor presentation
Docs: "EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit - Interim safety data from the Phase 2 DAVIO 2 trial continues to demonstrate EYP-1901 is well tolerated with no reported drug-related ocular or systemic SAEs - - Patient demographics demonstrate the Phase 2 DAVIO 2 population has a better baseline BCVA and decreased CST compared to the Phase 1 DAVIO trial cohort at trial start- - Phase 2 DAVIO 2 clinical trial remains on track to report topline data in December 2023 - WATERTOWN, Mass., July 27, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced interim m...",
"EYP-1901 PHASE 1 DAVIO CLINICAL"
07/11/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1"
07/10/2023 8-K Quarterly results
05/18/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...
Docs: "PRODUCT RIGHTS AGREEMENT between EyePoint Pharmaceuticals, Inc. and Alimera Sciences, Inc.",
"COMMERCIAL SUPPLY AGREEMENT This COMMERCIAL SUPPLY AGREEMENT is made as of May 17, 2023 , by and between EyePoint Pharmaceuticals, Inc., a Delaware corporation with its principal place of business at 480 Pleasant Street, Suite C-400, Watertown, MA 02472 , and Alimera Sciences, Inc., a Delaware corporation with its principal place of business at 6310 Town Square, Suite 400, Alpharetta, GA 30005 . Capitalized terms used, but not otherwise defined, in this Agreement have the meanings assigned to them in the Product Rights Agreement . RECITALS Whereas, EyePoint owns the rights to, and has commercialized in the United States, YUTIQ® 0.18 mg , which was approved by the U.S. Food and Drug Administration for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye...",
"EyePoint Pharmaceuticals Announces Sale of YUTIQ® to Alimera Sciences, Inc. for $82.5 Million Cash Plus Royalties –$75M paid at closing with an additional $7.5M payable in equal quarterly installments in 2024 – All outstanding bank debt retired and expected cash runway extended into 2025 – EyePoint well-capitalized beyond key EYP-1901 Phase 2 DAVIO 2 and PAVIA clinical trial inflection points WATERTOWN, Mass., May 18, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that it has entered into a definitive agreement for the sale of YUTIQ® 0.18mg to Alimera Sciences, Inc. . YUTIQ is a treatment for chronic non-infectious uveitis affecting the posterior segment ..."
05/03/2023 8-K Quarterly results
03/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EyePoint Pharmaceuticals Completes Enrollment in Oversubscribed Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for Maintenance Treatment of Wet AMD - Significant investigator and patient interest drove strong recruitment, exceeding enrollment goals - Topline DAVIO 2 data anticipated in Q4 2023 WATERTOWN, Mass., March 27, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it has completed enrollment in the Phase 2 "Durasert® and Vorolanib in Ophthalmology 2" clinical trial evaluating EYP-1901 as a potential six-month maintenance treatment for wet age-related macular degeneration . The trial exceeded its original target of 144 patients, enrolling a total of..."
03/10/2023 8-K Other Events  Interactive Data
03/02/2023 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Corporate Developments – Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 – – Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy on track with enrollment completion anticipated in 4Q 2023 – – Net product revenues for Full Year 2022 of $39.9 million, a 13.0% increase versus Full Year 2021 of $35.3 million – – $144.6M of cash and investments at December 31, 2022 with cash runway projected into 2H 2024 – – Management to host a conference call and webcast today at 8:30 a.m. ET – WATERTOWN, Mass., March 2, 2023 – EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve..."
01/23/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "EyePoint Pharmaceuticals Enters Lease Agreement for the Construction of a Commercial Manufacturing Facility for Global Product Supply of EYP-1901 and YUTIQ – State-of-the-art cGMP manufacturing facility to be built in Northbridge, Massachusetts – – Awarded $1.9 million of state and local grants with rent commencing in second half of 2024 – WATERTOWN, Mass, January 23, 2023 – EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has entered into a lease agreement to design and construct a 40,000-square-foot manufacturing facility in Northbridge, Massachusetts to support the global manufacturing of programs, including EYP-1901 and YUTI..."
01/12/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1"
01/06/2023 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "FIRST amendment to employment agreement",
"FIRST amendment to employment LETTER agreement",
"Recitals WHEREAS, Employee serves as the Chief Financial Officer of the Company; WHEREAS, Employee has previously entered into an Employment Agreement with the Company, as amended to the date hereof ; and WHEREAS, the Company desires to enter into a new employment agreement with Employee to ensure that Employee is retained on a full-time basis in accordance with the terms and conditions set forth herein. Agreement NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and Employee hereby agree as follows: 1. Position, Duties and Place of Employment. Employee will be employed by the Company pursuant to this Agreemen...",
"Recitals WHEREAS, Employee serves as the Chief Commercial Officer of the Company; WHEREAS, Employee has previously entered into an Employment Agreement with the Company, as amended to the date hereof ; and WHEREAS, the Company desires to enter into a new employment agreement with Employee to ensure that Employee is retained on a full-time basis in accordance with the terms and conditions set forth herein. Agreement NOW, THEREFORE, in consideration of the mutual covenants contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the Company and Employee hereby agree as follows: 1. Position, Duties and Place of Employment. Employee will be employed by the Company pursuant to this Agreeme...",
"EyePoint Pharmaceuticals Provides Business Update and Key 2023 Clinical Timelines – Topline data for Phase 2 DAVIO 2 clinical trial in wet AMD expected in 4Q 2023 – – Enrollment remains on-track in Phase 2 DAVIO 2 clinical trial for wet AMD and Phase 2 PAVIA clinical trial for NPDR – – Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021 – – Cash and investments of approximately $144 million as of December 31, 2022 – WATERTOWN, Mass, January 5, 2023 – EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced a business update and key 2023 clinical timelines for its lead product candidate, EYP-1901. EYP-1901 i...",
"EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer Dr. Duker has served as EyePoint’s Chief Operating Officer since November 2021 WATERTOWN, Mass., January 4, 2023 – EyePoint Pharmaceuticals, Inc. , a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that Jay S. Duker, M.D., who has served as the company’s Chief Operating Officer since November 2021, has been promoted to the additional role of President. In addition to continuing to oversee his duties as COO, in his expanded role, Dr. Duker will also oversee regulatory affairs. “Jay has been a tremendous asset to our team since he joined as COO, and we look forward to continuing to ben..."
11/16/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/02/2022 8-K Quarterly results
10/11/2022 8-K Termination of a Material Definitive Agreement  Interactive Data
09/29/2022 8-K Quarterly results
09/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "VOROLANIB VOROLANIB VOROLANIB VEGF-A VEGF-B VEGF-C VEGF-D R1"
08/30/2022 8-K Other Events  Interactive Data
08/03/2022 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments – First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists 2022 Annual Meeting – – Announced in conjunction with OcuMension Therapeutics, approval of New Drug Application by China’s National Medical Products Administration for YUTIQ® for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye – – Net product revenue of $11.3 million in Q2 2022; a 30% increase from Q2 2021 – – Management to host a conference call and webcast today at 8:30 a.m...."
07/18/2022 8-K Quarterly results
07/14/2022 8-K Quarterly results
06/24/2022 8-K Quarterly results
05/13/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
03/03/2022 8-K Quarterly results
02/14/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Presentation"
01/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, by and between EyePoint Pharmaceuticals, Inc. and Michael, C. Pine",
"EyePoint Pharmaceuticals Appoints Michael C. Pine as Chief Corporate Development and Strategy Officer"
01/10/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievements – Updated results from the Phase 1 DAVIO study of EYP-1901 for wet AMD continue to show positive safety and efficacy results out to eight months. Further results to be presented at the February Angiogenesis 2022 virtual meeting –",
"Corporate Presentation"
12/10/2021 8-K Quarterly results
11/19/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among EyePoint Pharmaceuticals, Inc. and Cowen and Company, LLC and Guggenheim Securities, LLC",
"Form of Pre-Funded Warrant to Purchase Common Stock",
"Opinion of Hogan Lovells US LLP",
"EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock",
"EyePoint Pharmaceuticals Announces Pricing of Public Offering",
"EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering"
11/15/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Exhibit 99.1 EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD",
"EYP-1901 Phase 1 DAVIO Study Interim Results Presentation of EyePoint Pharmaceuticals, Inc."
11/03/2021 8-K Quarterly results
Docs: "EyePoint Pharmaceuticals Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments – Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at American Society of Retina Specialists –"
11/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement, effective November 1, 2021, between EyePoint Pharmaceuticals, Inc. and Jay S. Duker, M.D",
"EyePoint Pharmaceuticals Appoints Jay S. Duker, M.D. as Chief Operating Officer"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy